Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money ...

“Third, Biogen’s been running on fumes while it works on its Alzheimer’s drug, but the fumes, basically a very good MS drug, in a crowded field, aren’t enough. Not with the unmet projectio ...

Some neurologists have even started talking about the possibility that the drugs could not only slow down progression of MS, but even potentially offer a functional cure. Biogen licensed rights to ...

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ ...